[go: up one dir, main page]

PT1171578E - Composicao farmaceutica compreendendo as celulas nkt activadas pelo pim e sua utilizacao em terapia - Google Patents

Composicao farmaceutica compreendendo as celulas nkt activadas pelo pim e sua utilizacao em terapia

Info

Publication number
PT1171578E
PT1171578E PT00920847T PT00920847T PT1171578E PT 1171578 E PT1171578 E PT 1171578E PT 00920847 T PT00920847 T PT 00920847T PT 00920847 T PT00920847 T PT 00920847T PT 1171578 E PT1171578 E PT 1171578E
Authority
PT
Portugal
Prior art keywords
pim
pharmaceutical composition
therapy
nkt cells
cells activated
Prior art date
Application number
PT00920847T
Other languages
English (en)
Inventor
Philippe Kourilsky
Irina Apostolov
Gabriel Gachelin
Yousuke Takahama
Original Assignee
Inst Nat Sante Rech Med
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Pasteur Institut filed Critical Inst Nat Sante Rech Med
Publication of PT1171578E publication Critical patent/PT1171578E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT00920847T 1999-04-19 2000-04-19 Composicao farmaceutica compreendendo as celulas nkt activadas pelo pim e sua utilizacao em terapia PT1171578E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9904897A FR2792205B1 (fr) 1999-04-19 1999-04-19 Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie

Publications (1)

Publication Number Publication Date
PT1171578E true PT1171578E (pt) 2003-11-28

Family

ID=9544579

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00920847T PT1171578E (pt) 1999-04-19 2000-04-19 Composicao farmaceutica compreendendo as celulas nkt activadas pelo pim e sua utilizacao em terapia

Country Status (12)

Country Link
US (2) US7052909B1 (pt)
EP (2) EP1346725A1 (pt)
JP (1) JP2003502284A (pt)
AT (1) ATE243252T1 (pt)
CA (1) CA2368029A1 (pt)
DE (1) DE60003417T2 (pt)
DK (1) DK1171578T3 (pt)
ES (1) ES2206221T3 (pt)
FR (1) FR2792205B1 (pt)
HK (1) HK1044795B (pt)
PT (1) PT1171578E (pt)
WO (1) WO2000063348A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ505538A (en) * 2000-07-03 2004-12-24 Malaghan Inst Of Medical Res A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
FR2815641B1 (fr) * 2000-10-24 2002-12-27 Pasteur Institut Procede de criblage de molecules actives dans la prevention et le traitement des lesions atherosclereuses et ses applications
WO2004018002A2 (en) * 2002-08-23 2004-03-04 Gabriele Multhoff Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
WO2006009731A1 (en) * 2004-06-18 2006-01-26 Genentech, Inc. Methods of using apo2l receptor agonists and nk cell activators
FR2908658B1 (fr) * 2006-11-20 2011-11-11 Centre Nat Rech Scient Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69840528D1 (de) * 1997-04-10 2009-03-19 Kyowa Hakko Kirin Co Ltd NKT-Zellenaktivatoren, die Alpha-Glycosylceramide enthalten
CA2302155A1 (en) * 1997-09-12 1999-03-18 Brigham & Women's Hospital Synthetic antigens for cd1-restricted immune responses
AU3558899A (en) * 1998-04-13 1999-11-01 Brigham And Women's Hospital Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof

Also Published As

Publication number Publication date
FR2792205A1 (fr) 2000-10-20
CA2368029A1 (fr) 2000-10-26
DE60003417T2 (de) 2004-05-06
EP1171578B1 (fr) 2003-06-18
JP2003502284A (ja) 2003-01-21
WO2000063348A3 (fr) 2000-12-28
FR2792205B1 (fr) 2001-07-27
ATE243252T1 (de) 2003-07-15
US20060263376A1 (en) 2006-11-23
EP1171578A2 (fr) 2002-01-16
HK1044795A1 (en) 2002-11-01
HK1044795B (zh) 2003-10-10
WO2000063348A2 (fr) 2000-10-26
ES2206221T3 (es) 2004-05-16
DE60003417D1 (de) 2003-07-24
US7052909B1 (en) 2006-05-30
EP1346725A1 (fr) 2003-09-24
DK1171578T3 (da) 2003-10-13

Similar Documents

Publication Publication Date Title
SG131943A1 (en) Specific binding agents to hepatocyte growth factor
IL142647A0 (en) A method and kit for measuring proteasome activity
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
SE0202114L (sv) Polymeraffinitetsmatris, förfarande för framställning därav och anvädning därav
ATE344801T1 (de) Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
DE69837393D1 (de) Stimulierung von hämatopoietischen zellen im vitro
NO20073489L (no) Fremgangsmate og apparat for a levere epinephrine
NO975716L (no) Imidazolforbindelser
DE69635671D1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
NO864203L (no) Biologiske makromolekyler.
DE60122337D1 (de) Verwendung von taci als antitumormittel
PT1171578E (pt) Composicao farmaceutica compreendendo as celulas nkt activadas pelo pim e sua utilizacao em terapia
DK0414019T3 (da) Substituerede N-(quinolin-2-yl-methoxy)benzyl-sulfonylurinstoffer
AR024523A1 (es) Metodo para aumentar la sobrevida de un injerto por modulacion de la actividad de hemo oxigenasa
AU2001290574A1 (en) Method and apparatus for measuring the hemoglobin concentration and/or hematocrit in whole blood using diffuse light
ES2183890T3 (es) Uso del factor de crecimiento de hepatocitos para in estimular la proliferacion y diferenciacion de celulas hematopoyeticas.
IL138048A0 (en) Use of inhibitors of mammalian asparaginyl endopeptidase for therapy of autoimmune disease
Liu et al. Inhibition of creatine kinase activity and alterations in electrophoretic mobility by palladium ions
ES2002133A6 (es) Dispositivo para la determinacion de un grupo sanguineo
GR3015373T3 (en) 2-Halogen-substituted N-indolyl sulfonic-acid amides, process for their preparation and their pharmaceutical use.
ES2180586T3 (es) Procedimiento para la determinacion de un analito.
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
RU2000117703A (ru) Способ предпосевной обработки семян
KR920000943A (ko) 시험관내 조직의 생존력 및 증식능 측정을 위한 천연-상태 방법 및 시스템